Profusa (NASDAQ:PFSA – Get Free Report) and ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.
Profitability
This table compares Profusa and ClearPoint Neuro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profusa | N/A | N/A | -1,731.09% |
| ClearPoint Neuro | -81.76% | -188.09% | -40.88% |
Analyst Ratings
This is a breakdown of current ratings for Profusa and ClearPoint Neuro, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profusa | 1 | 0 | 0 | 0 | 1.00 |
| ClearPoint Neuro | 1 | 0 | 2 | 0 | 2.33 |
Risk and Volatility
Profusa has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
Valuation and Earnings
This table compares Profusa and ClearPoint Neuro”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profusa | $100,000.00 | 4.67 | -$35.82 million | ($5,619.96) | -0.00 |
| ClearPoint Neuro | $42.28 million | 7.62 | -$25.54 million | ($1.18) | -8.95 |
ClearPoint Neuro has higher revenue and earnings than Profusa. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
9.8% of Profusa shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 15.0% of Profusa shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
ClearPoint Neuro beats Profusa on 10 of the 14 factors compared between the two stocks.
About Profusa
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
